logo-loader

NetTargets

Market:
Unlisted
Market Cap:
-
Price
-
Change
-
52 weeks high
-
52 weeks low
-

In brief

South Korea-based KAIST spinout startup, NetTargets is developing two high-performance drug development platforms, mechanism analysis platform (N-MAP) and compound analysis platform (N-CAP) on the basis of artificial intelligence (AI)-enhanced systems biology. The company is established on over-20-year research in systems biology (http://sbie.kaist.ac.kr). Using their strong expertise to integrate mathematical modeling, computer simulations, and biological experiments, NetTargets provides a clear understanding of dynamic interactions among multiple components of a biological system and the behavior of the system as a whole. The mechanism analysis platform N-MAP is aimed at clarifying the drug-disease mechanism by decoding bio-complexity to unravel therapeutic strategies, and N-CAP facilitates drug candidate validation, reverse analysis to check off-target effects in the mechanism, and promising drug candidate synthesis.